Pfizer Inc Joins £10 Million Bioprocessing Research Programme
News Mar 26, 2010
The BBSRC has announced the launch of the second round of funding for the Bioprocessing Industry Research Club (BRIC).
The 17 current industry members have agreed to continue their support for a second 5 year academic research programme, and are joined by new member, Pfizer Inc. Dr John Mott from the Pfizer, St Louis, USA laboratories spoke to a BRIC scientific meeting in Birmingham, where he described the importance of biopharmaceutical bioprocessing for Pfizer.
The club funds research in all aspects of bioprocessing of biologics, but applications in priority research areas will be particularly welcomed by the steering group that assesses applications:
• Bioprocessing research challenges for protein products and their host cell producers
• High-throughput bioprocess development
• Effective modeling of whole bioprocesses
• Robust and effective analytics for bioprocessing
• Bioprocessing research for cellular products.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE